David H. Bruining

David H. Bruining

Auto-generated profile, based on publicly available information

David H. Bruining

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JMJeffrey D. McCurdy
Jeffrey D. McCurdy
AJAndrea Jones
Andrea Jones
FEFelicity T. Enders
Felicity T. Enders
JKJill M. Killian
Jill M. Killian
ELEdward Loftus
Edward Loftus
DBDavid H. Bruining
David H. Bruining

1 August 2011 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
DBDavid H. Bruining
David H. Bruining
ELEdward Loftus
Edward Loftus
EEEric C. Ehman
Eric C. Ehman
HSHassan A. Siddiki
Hassan A. Siddiki
DNDouglas L. Nguyen
Douglas L. Nguyen
JFJoel G. Fletcher
Joel G. Fletcher

3 June 2020 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
DBDavid Henry Bruining
David Henry Bruining
SOSalvatore Oliva
Salvatore Oliva
MFMark R Fleisher
Mark R Fleisher
MFMonika Fischer
Monika Fischer
JFJoel G Fletcher
Joel G Fletcher
Introduction Crohn’s disease diagnosis and monitoring remains a great clinical challenge and often requires multiple testing modalities. Assessing Crohn’s disease activity in the entire gastrointestinal (GI) tract using a panenteric capsule endoscopy (CE) system could be used as an alternative to colonoscopy and cross-sectional imaging. This study assessed the accuracy and safety of panenteric CE in Crohn’s disease as compared with ileocolonoscopy (IC) and/or magnetic resonance enterography (MRE). Methods A prospective, multicentre study was performed in subjects with established Crohn’s disease. Individuals with proven small bowel patency underwent a standardised bowel preparation, followed by CE ingestion and IC either the same or following day. MRE, IC, and CE interpretations were performed by blinded central readers using validated scoring systems. The primary endpoint was the overall sensitivity of CE vs MRE and/or IC in Crohn’s disease subjects. Results Study enrolment included 158 subjects from 21 sites in the USA, Austria, and Israel. Of those, 99 were included in the analysis. Imaging modality scores indicated none to mild inflammation in the proximal small bowel and colon, but discrepant levels of inflammation in the terminal ileum. Overall sensitivity for active enteric inflammation (CE vs MRE and/or IC) was 94% vs 100% (p=0.125) and specificity was 74% vs 22% (p=0.001). Sensitivity of CE was superior to MRE for enteric inflammation in the proximal small bowel (97% vs 71%, p=0.021), and similar to MRE and/or IC in the terminal ileum and colon (p=0.500–0.625). There were seven serious adverse advents of which three were related to the CE device. Conclusion Panenteric CE is a reliable tool for assessing Crohn’s disease mucosal activity and extent compared with more invasive methods. This study demonstrates high performance of the panenteric CE as compared to MRE and/or IC without the need for multiple tests in non-stricturing Crohn’s disease. Trial registration number ClinicalTrials.gov NCT03241368

10 July 2012 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AMA. B. Mohabbat
A. B. Mohabbat
WSW. J. Sandborn
W. J. Sandborn
ELEdward Loftus
Edward Loftus
RWR. H. Wiesner
R. H. Wiesner
DBD. H. Bruining
D. H. Bruining
Background Ulcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post-transplantation immunosuppressive therapy. Aim To evaluate the efficacy and safety of anti-tumour necrosis factor (anti-TNF) agents for the management of IBD following OLT. Methods We reviewed the records of patients with a diagnosis of IBD who underwent OLT at Mayo Clinic Rochester between 1985 and 2009. Patients were included if they had received anti-TNF therapy post-OLT. Clinical response was defined as a physician's assessment of improvement after 12 weeks of anti-TNF usage, and mucosal healing was defined as the absence of ulcerations on follow-up endoscopy. Results The median age of the eight study patients was 42.0 years and 37.5% were female patients. All had been diagnosed with IBD prior to OLT (UC in three and Crohn's disease in five). Indication for OLT was cirrhotic stage primary sclerosing cholangitis (PSC), and three concomitantly had cholangiocarcinoma. Clinical response was demonstrated in seven of eight patients (87.5%) and mucosal healing was demonstrated in three of seven (42.9%). Four infections (oral candidiasis, Clostridium difficile colitis, bacterial pneumonia and cryptosporidiosis) in three patients were reported. One patient developed an Epstein–Barr virus-positive post-transplant lympho-proliferative disorder. One death occurred due to complications from recurrent PSC. Conclusions Starting Anti-TNF therapy following orthotopic liver transplantation appears to be a potential option for inflammatory bowel disease management. Additional studies are needed, however, to confirm these findings and to further assess risks associated with this treatment strategy.

31 January 2015 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
DBDavid H. Bruining
David H. Bruining
GBGauraang Bhatnagar
Gauraang Bhatnagar
JRJordi Rimola
Jordi Rimola
STStuart A. Taylor
Stuart A. Taylor
EZEllen M. Zimmermann
Ellen M. Zimmermann
JFJoel G. Fletcher
Joel G. Fletcher

1 March 2014 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NWNicholas K Weber
Nicholas K Weber
JFJeff L Fidler
Jeff L Fidler
TKTony M Keaveny
Tony M Keaveny
BCBart L Clarke
Bart L Clarke
SKSundeep Khosla
Sundeep Khosla
DBDavid H Bruining
David H Bruining
Ty (BMD) from noncontrast CT images. This study seeks to determine whether this advanced technology can be applied to patients with IBD undergoing CT enterography (CTE) with IV contrast. METHODS: Patients with IBD who underwent a CTE and DXA scan between 2007 and 2011 were retrospectively identified. Femoral neck BMD (g/cm2) andT-scores were measured and compared between DXA and BCT analysis of the CTE images. Femoral strength (Newtons) was also determined from BCT analysis. RESULTS: DXA- and CTE-generated BMDT-score values were highly correlated (R2=0.84,P<0.0001) in this patient cohort (n=136). CTE identified patients with both osteoporosis (sensitivity, 85.7%; 95% confidence interval (CI), 48.7–97.4 and specificity, 98.5%; 95% CI, 94.5–99.6) and osteopenia (sensitivity, 85.1%; 95% CI, 72.3–92.6 and specificity, 85.4%; 95% CI, 76.6–91.3). Of the 16 patients who had “fragile” bone strength by BCT (placing them at the equivalent high risk of fracture as for osteoporosis), 6 had osteoporosis and 10 had osteopenia by DXA. CONCLUSIONS: CTE scans can provide hip BMD,T-scores, and clinical classifications that are comparable to those obtained from DXA; when combined with BCT analysis, CTE can identify a subset of patients with osteopenia who have clinically relevant fragile bone strength. This technique could markedly increase bone health assessments in IBD patients already undergoing CTE to evaluate small bowel disease....